retatrutide d Demand for Unapproved Weight-Loss Drug Surges on Social Media Retatrutide Promises Big Weight Loss,

Adverse events caused 12.2% and 18.2% of patients to stop taking the 9 mg and 12 mg doses respectively, compared to 4% stopping placebo

Why This Question Comes Up The stacking question is intuitive: if one GLP-1 compound drives weight loss, wouldn't two drive more

retatrutide doesnt, and wont for several years

[2] Additionally, GLP-1 agonists may be prescribed for individuals with type 2 diabetes who have coexisting conditions such as atherosclerosis, heart failure, or chronic kidney disease, as these medications have demonstrated potential benefits beyond glycemic control

Not recommended for regular use with GLP-1 medications